NCT01879423View on ClinicalTrials.gov

The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 5mg×5 Compared With Lamotrigine Compressed Tablet 25mg in Chinese Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 28, 2013

Primary Completion Date

June 6, 2013

Study Completion Date

June 6, 2013

Conditions
Epilepsy
Interventions
DRUG

Lamotrigine Dispersible/Chewable tablets 5mg*5

Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg\*1 tablet at Day15

DRUG

Lamotrigine Compressed tablet 25mg

Single dose of lamotrigine compressed 25mg\*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day15

Trial Locations (1)

200030

GSK Investigational Site, Shanghai

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01879423 - The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 5mg×5 Compared With Lamotrigine Compressed Tablet 25mg in Chinese Healthy Male Subjects | Biotech Hunter | Biotech Hunter